Cargando…

Anti-BCMA chimeric antigen receptors with fully human heavy-chain-only antigen recognition domains

Chimeric antigen receptor (CAR)-expressing T cells targeting B-cell maturation antigen (BCMA) have activity against multiple myeloma, but improvements in anti-BCMA CARs are needed. We demonstrated recipient anti-CAR T-cell responses against a murine single-chain variable fragment (scFv) used clinica...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lam, Norris, Trinklein, Nathan D., Buelow, Benjamin, Patterson, George H., Ojha, Namrata, Kochenderfer, James N.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6962219/ https://www.ncbi.nlm.nih.gov/pubmed/31941907 http://dx.doi.org/10.1038/s41467-019-14119-9

Ejemplares similares

Author Correction: Anti-BCMA chimeric antigen receptors with fully human heavy-chain-only antigen recognition domains
por: Lam, Norris, et al.
Publicado: (2020)

T cells expressing CD5/CD7 bispecific chimeric antigen receptors with fully human heavy-chain-only domains mitigate tumor antigen escape
por: Dai, Zhenyu, et al.
Publicado: (2022)

The rational development of CD5-targeting biepitopic CARs with fully human heavy-chain-only antigen recognition domains
por: Dai, Zhenyu, et al.
Publicado: (2021)

Novel BCMA-OR-CD38 tandem-dual chimeric antigen receptor T cells robustly control multiple myeloma
por: Feng, Yaru, et al.
Publicado: (2021)

Comprehensive meta-analysis of anti-BCMA chimeric antigen receptor T-cell therapy in relapsed or refractory multiple myeloma
por: Zhang, Lina, et al.
Publicado: (2021)

Characterization of novel dual tandem CD19/BCMA chimeric antigen receptor T cells to potentially treat multiple myeloma
por: Kang, Liqing, et al.
Publicado: (2020)

Preclinical Evaluation of Invariant Natural Killer T Cells Modified with CD38 or BCMA Chimeric Antigen Receptors for Multiple Myeloma
por: Poels, Renée, et al.
Publicado: (2021)

Non-Conventional Allogeneic Anti-BCMA Chimeric Antigen Receptor-Based Immune Cell Therapies for Multiple Myeloma Treatment
por: Du, Zhicheng, et al.
Publicado: (2023)

Targeting B Cell Maturation Antigen (BCMA) in Multiple Myeloma: Potential Uses of BCMA-Based Immunotherapy
por: Cho, Shih-Feng, et al.
Publicado: (2018)

High antigen density of BCMA: friend or foe to CAR T cells?
por: Gaballa, Mahmoud R, et al.
Publicado: (2022)

Molecular Characterization of a Fully Human Chimeric T-Cell Antigen Receptor for Tumor-Associated Antigen EpCAM
por: Shirasu, Naoto, et al.
Publicado: (2012)

Fully human CD19-specific chimeric antigen receptors for T-cell therapy
por: Sommermeyer, Daniel, et al.
Publicado: (2017)

Preclinical Efficacy of BCMA-Directed CAR T Cells Incorporating a Novel D Domain Antigen Recognition Domain
por: Buonato, Janine M., et al.
Publicado: (2022)

Corrigendum to “Molecular Characterization of a Fully Human Chimeric T-Cell Antigen Receptor for Tumor-Associated Antigen EpCAM”
por: Shirasu, Naoto, et al.
Publicado: (2015)

Bilateral anterior cerebral artery occlusion following CD19- and BCMA-targeted chimeric antigen receptor T-cell therapy for a myeloma patient
por: Wang, Li-xia, et al.
Publicado: (2021)

Vγ9Vδ2 T cells expressing a BCMA—Specific chimeric antigen receptor inhibit multiple myeloma xenograft growth
por: Zhang, Xi, et al.
Publicado: (2022)

Role of Anti-B-Cell Maturation Antigen (BCMA) in the Management of Multiple Myeloma
por: Rinaldi, Ikhwan, et al.
Publicado: (2022)

Sequence-Based Discovery Demonstrates That Fixed Light Chain Human Transgenic Rats Produce a Diverse Repertoire of Antigen-Specific Antibodies
por: Harris, Katherine E., et al.
Publicado: (2018)

Is Prophylaxis the Only Way Out for Cytokine Release Syndrome Associated With Chimeric Antigen T-cell Therapy?
por: Dave, Prashil, et al.
Publicado: (2021)

B-cell maturation antigen (BCMA) in multiple myeloma: the new frontier of targeted therapies
por: Sanchez, Larysa, et al.
Publicado: (2021)

CAR-T-Cell Therapy in Multiple Myeloma: B-Cell Maturation Antigen (BCMA) and Beyond
por: Mishra, Abhinava K., et al.
Publicado: (2023)

Chimeric antigen receptor (CAR) T therapies for the treatment of hematologic malignancies: clinical perspective and significance
por: Boyiadzis, Michael M., et al.
Publicado: (2018)

Engineering Chimeric Antigen Receptors
por: Kulemzin, S. V., et al.
Publicado: (2017)

Case Report: Reversible Neurotoxicity and a Clinical Response Induced by BCMA-Directed Chimeric Antigen Receptor T Cells Against Multiple Myeloma With Central Nervous System Involvement
por: Zhang, Ying, et al.
Publicado: (2021)

Bench‐to‐bedside translation of chimeric antigen receptor (CAR) T cells using a multiscale systems pharmacokinetic‐pharmacodynamic model: A case study with anti‐BCMA CAR‐T
por: Singh, Aman P., et al.
Publicado: (2021)

Effectiveness and safety of anti-BCMA chimeric antigen receptor T-cell treatment in relapsed/refractory multiple myeloma: a comprehensive review and meta-analysis of prospective clinical trials
por: Hu, Dingyuan, et al.
Publicado: (2023)

B-cell maturation antigen (BCMA) in multiple myeloma: rationale for targeting and current therapeutic approaches
por: Shah, Nina, et al.
Publicado: (2020)

Mechanisms of antigen escape from BCMA- or GPRC5D-targeted immunotherapies in multiple myeloma
por: Lee, Holly, et al.
Publicado: (2023)

Chimeric antigen receptors that trigger phagocytosis
por: Morrissey, Meghan A, et al.
Publicado: (2018)

Chimeric Antigen Receptors for T-Cell Malignancies
por: Scherer, Lauren D., et al.
Publicado: (2019)

Engineering and Design of Chimeric Antigen Receptors
por: Guedan, Sonia, et al.
Publicado: (2018)

The Chimeric Antigen Receptor Detection Toolkit
por: Hu, Yifei, et al.
Publicado: (2020)

Chimeric antigen receptor T-cell therapy
por: Burge, Cale, et al.
Publicado: (2023)

Multi-antigen-targeted chimeric antigen receptor T cells for cancer therapy
por: Han, Xiao, et al.
Publicado: (2019)

Chimeric Antigen Receptors Expand the Repertoire of Antigenic Macromolecules for Cellular Immunity
por: Keane, John T., et al.
Publicado: (2021)

A simple and robust clinical manufacturing process for the ex-vivo expansion of autologous T cells genetically engineered to express an anti-BCMA chimeric antigen receptor (CAR) for the treatment of multiple myeloma
por: Ladd, Alden, et al.
Publicado: (2015)

Anti-TACI single and dual-targeting CAR T cells overcome BCMA antigen loss in multiple myeloma
por: Larson, Rebecca C., et al.
Publicado: (2023)

Antigen recognition
Publicado: (1996)

Computationally Guided Design of Single-Chain Variable Fragment Improves Specificity of Chimeric Antigen Receptors
por: Krokhotin, Andrey, et al.
Publicado: (2019)

T cell receptor β-chain-targeting chimeric antigen receptor T cells against T cell malignancies
por: Li, Fanlin, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_let02l1qnkt07p6fvd4bmukoiv